Please use this identifier to cite or link to this item:
https://doi.org/10.1371/journal.pone.0173279
Title: | Validation of a commercially available test that enables the quantification of the numbers of CGG trinucleotide repeat expansion in FMR1 gene | Authors: | Lim G.X.Y. Yeo M. Koh Y.Y. Winarni T.I. Rajan-Babu I.-S. Chong S.S. Faradz S.M.H. Guan M. |
Keywords: | allele consensus genotype human major clinical study mutation polymerase chain reaction quantitative study reproducibility trinucleotide repeat validation process female fragile X syndrome genetics male trinucleotide repeat validation study DNA FMR1 protein, human fragile X mental retardation protein DNA Female Fragile X Mental Retardation Protein Fragile X Syndrome Genotype Humans Male Mutation Polymerase Chain Reaction Trinucleotide Repeat Expansion |
Issue Date: | 2017 | Publisher: | Public Library of Science | Citation: | Lim G.X.Y., Yeo M., Koh Y.Y., Winarni T.I., Rajan-Babu I.-S., Chong S.S., Faradz S.M.H., Guan M. (2017). Validation of a commercially available test that enables the quantification of the numbers of CGG trinucleotide repeat expansion in FMR1 gene. PLoS ONE 12 (3) : e0173279. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0173279 | Abstract: | In the present study, we evaluated a commercially available TP-PCR-based assay, the FastFraX™ FMR1 Sizing kit, as a test in quantifying the number of CGG repeats in the FMR1 gene. Based on testing with well characterized DNA samples from Coriell, the kit yielded size results within 3 repeats of those obtained by common consensus (n = 14), with the exception of one allele. Furthermore, based on data obtained using all Coriell samples with or without common consensus (n = 29), the Sizing kit was 97.5% in agreement with existing approaches. Additionally, the kit generated consistent size information in repeatability and reproducibility studies (CV 0.39% to 3.42%). Clinical performance was established with 198 archived clinical samples, yielding results of 100% sensitivity (95% CI, 91.03% to 100%) and 100% specificity (95% CI, 97.64% to 100%) in categorizing patient samples into the respective normal, intermediate, premutation and full mutation genotypes. © 2017 Lim et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | Source Title: | PLoS ONE | URI: | https://scholarbank.nus.edu.sg/handle/10635/166016 | ISSN: | 19326203 | DOI: | 10.1371/journal.pone.0173279 |
Appears in Collections: | Elements Staff Publications |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_1371_journal_pone_0173279.pdf | 1.06 MB | Adobe PDF | OPEN | None | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.